相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors
Martin Gutierrez et al.
CLINICAL CANCER RESEARCH (2021)
Peripheral T cell expansion predicts tumour infiltration and clinical response
Thomas D. Wu et al.
NATURE (2020)
Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors
Bonnie S. Glisson et al.
CLINICAL CANCER RESEARCH (2020)
An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors
Rui Wang et al.
CLINICAL CANCER RESEARCH (2019)
The promise and challenges of immune agonist antibody development in cancer
Patrick A. Mayes et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
A first-in-human (FIH) study of PF-04518600 (PF-8600) OX40 agonist in adult patients (pts) with select advanced malignancies
A. Diab et al.
ANNALS OF ONCOLOGY (2017)
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40
David J. Messenheimer et al.
CLINICAL CANCER RESEARCH (2017)
Rationale for anti-OX40 cancer immunotherapy
Sandrine Aspeslagh et al.
EUROPEAN JOURNAL OF CANCER (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al.
LANCET (2016)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Heterogeneity of cytotoxic T cell infiltration in breast and colorectal cancer
James Ziai et al.
Journal for ImmunoTherapy of Cancer (2015)
Nonclinical safety assessment of a humanized anti-OX40 agonist antibody, MOXR0916
R. Prell et al.
EUROPEAN JOURNAL OF CANCER (2014)
PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer
Zhiqiang Guo et al.
PLOS ONE (2014)
Combined Targeting of Costimulatory (OX40) and Coinhibitory (CTLA-4) Pathways Elicits Potent Effector T Cells Capable of Driving Robust Antitumor Immunity
William L. Redmond et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes
Lidia Robert et al.
ONCOIMMUNOLOGY (2014)
OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
Brendan D. Curti et al.
CANCER RESEARCH (2013)
Molecular mechanisms of T cell co-stimulation and co-inhibition
Lieping Chen et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity
Naomi Kitamura et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
Daniel Hirschhorn-Cymerman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
Silvia Piconese et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134)
JK Petty et al.
AMERICAN JOURNAL OF SURGERY (2002)
Immunohistochemical analysis of primary breast tumors and tumor draining lymph nodes by means of the T-cell costimulatory molecule OX-40
T Ramstad et al.
AMERICAN JOURNAL OF SURGERY (2000)
分享论文
